BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8944340)

  • 1. Lack of expression of dopamine D2 receptors in malignant melanoma: evidence for interaction of iodobenzofurans with melanin.
    Böni R; Steinert H; Böni RA; Lichtensteiger W; Dummer R; Hartman DS; von Schulthess GK; Burg G; Westera G
    Dermatology; 1996; 193(3):198-202. PubMed ID: 8944340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dopamine-D2 receptor scintigraphy with 123I-iodobenzofuran in malignant melanoma].
    Steinert H; Huch-Böni RA; Böni R; Westera G; Buck A
    Nuklearmedizin; 1995 Aug; 34(4):146-50. PubMed ID: 7675644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo.
    Larisch R; Schulte KW; Vosberg H; Ruzicka T; Müller-Gärtner HW
    J Nucl Med; 1998 Jun; 39(6):996-1001. PubMed ID: 9627332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D1 dopamine receptors are not expressed in human melanoma.
    Böni R; Lichtensteiger W; Steinert HC; Böni RA; Früh H; Dummer R; Hartmann DG; Laine E; Burg G
    Melanoma Res; 1997 Apr; 7(2):117-9. PubMed ID: 9167177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioiodine-labelled alpha-methyl-tyrosine in malignant melanoma: cell culture studies and results in patients.
    Böni R; Steinert H; Huch Böni R; Von Schulthess GK; Meyer J; Dummer R; Burg G; Westera G
    Br J Dermatol; 1997 Jul; 137(1):96-100. PubMed ID: 9274632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase 1 clinical study of 123I-IBF, a new radioligand for evaluating dopamine D2 receptor with SPECT (I); biodistribution and dosimetry].
    Yonekura Y; Sadato N; Tsuchida T; Uematsu H; Nakamura S; Yamamoto K; Ishii Y
    Kaku Igaku; 1999 Feb; 36(2):145-53. PubMed ID: 10213982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase 2 clinical study of 123I-IBF, a dopamine D2 receptor imaging agent, to evaluate clinical efficacy and safety in Parkinson's disease and Parkinson syndromes].
    Torizuka K; Mizuno Y; Kubo A; Konishi J; Yonekura Y; Hatazawa J; Momose T; Murata M; Amano T; Fukuyama H; Kuwabara Y
    Kaku Igaku; 1999 Oct; 36(8):845-64. PubMed ID: 10586546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanin affinity of N-(2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent.
    Labarre P; Papon J; Moreau MF; Moins N; Bayle M; Veyre A; Madelmont JC
    Melanoma Res; 2002 Apr; 12(2):115-21. PubMed ID: 11930107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phase 1 clinical study of 123I-IBF, a new radioligand for evaluating Dopamine D2 receptor with SPECT (II); pharmacokinetics study and quantification in the brain].
    Yonekura Y; Sadato N; Tsuchida T; Uematsu H; Nakamura S; Onishi Y; Yamamoto K; Ishii Y
    Kaku Igaku; 1999 Feb; 36(2):155-68. PubMed ID: 10213983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas.
    Bodei L; Hofland LJ; Ferone D; Mooy CM; Kros JM; Paridaens DA; Baarsma SG; Ferdeghini M; Van Hagen MP; Krenning EP; Kwekkeboom DJ
    Cancer Biother Radiopharm; 2003 Dec; 18(6):895-902. PubMed ID: 14969602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial.
    Cachin F; Miot-Noirault E; Gillet B; Isnardi V; Labeille B; Payoux P; Meyer N; Cammilleri S; Gaudy C; Razzouk-Cadet M; Lacour JP; Granel-Brocard F; Tychyj C; Benbouzid F; Grange JD; Baulieu F; Kelly A; Merlin C; Mestas D; Gachon F; Chezal JM; Degoul F; D'Incan M
    J Nucl Med; 2014 Jan; 55(1):15-22. PubMed ID: 24263087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The characterization of IBF as a new selective dopamine D-2 receptor imaging agent.
    Kung MP; Kung HF; Billings J; Yang Y; Murphy RA; Alavi A
    J Nucl Med; 1990 May; 31(5):648-54. PubMed ID: 2140409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT.
    Ichise M; Ballinger JR; Tanaka F; Moscovitch M; St George-Hyslop PH; Raphael D; Freedman M
    J Nucl Med; 1998 Sep; 39(9):1511-8. PubMed ID: 9744333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metabolism of 123I-IBF in humans].
    Matsumoto H; Tanaka A; Suzuki N; Kondo S; KatoAzuma M; Yonekura Y
    Kaku Igaku; 1999 Feb; 36(2):169-77. PubMed ID: 10213984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compartmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects.
    Laruelle M; van Dyck C; Abi-Dargham A; Zea-Ponce Y; Zoghbi SS; Charney DS; Baldwin RM; Hoffer PB; Kung HF; Innis RB
    J Nucl Med; 1994 May; 35(5):743-54. PubMed ID: 8176454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a chimeric human dopamine D3/D2 receptor functionally coupled to adenylyl cyclase in Chinese hamster ovary cells.
    Van Leeuwen DH; Eisenstein J; O'Malley K; MacKenzie RG
    Mol Pharmacol; 1995 Aug; 48(2):344-51. PubMed ID: 7651368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo quantification of dopamine D2 receptor parameters in nonhuman primates with [123I]iodobenzofuran and single photon emission computerized tomography.
    Laruelle M; al-Tikriti MS; Zea-Ponce Y; Zoghbi SS; Baldwin RM; Charney DS; Hoffer PB; Kung HF; Innis RB
    Eur J Pharmacol; 1994 Sep; 263(1-2):39-51. PubMed ID: 7821360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration.
    Denoyer D; Potdevin T; Roselt P; Neels OC; Kirby L; Greguric I; Katsifis A; Dorow DS; Hicks RJ
    J Nucl Med; 2011 Jan; 52(1):115-22. PubMed ID: 21149487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents.
    Murphy RA; Kung HF; Kung MP; Billings J
    J Med Chem; 1990 Jan; 33(1):171-8. PubMed ID: 2136916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases.
    Froidevaux S; Calame-Christe M; Schuhmacher J; Tanner H; Saffrich R; Henze M; Eberle AN
    J Nucl Med; 2004 Jan; 45(1):116-23. PubMed ID: 14734683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.